World’s leading Cryogenic Stem Cell Storage Containers manufacturer Charter Medical Ltd has received CE Mark approval on its next generation Cell Freeze(R) Cryogenic Storage Containers for Hematopoietic Progenitor Cells (HPC’s). New approval will allow company to begin marketing and selling the newly designed and expanded product offering for cryogenic storage, preservation, and transfer of HPC’s in Europe. According to company’s officials, launch of this product in the Europe sets a strategic growth opportunity for the Cell-Freeze(R) product line. Combined will integrate company’ commitment to increase presence globally in the biotech and cellular therapy markets.
European approval will help company to get greater access to European markets, which comes as second key potential market for these types of containers. These storage durable containers offer a size range from 50 mL to 750 mL when frozen at ultralow (-196*C) temperatures.
Joe Petrosky, Vice President of Global Marketing and Sales for Charter Medical, stated: “We are excited at this launch of the Cell-Freeze(R) product family of cryogenic storage containers into Europe. These products serve several high growth markets including cellular therapy and have already received acceptance at several customers in the U.S.”
Charter Medical is subsidiary of Lydall, Inc. NYSE listed company, headquartered in Manchester. The Company has its operations in the U.S., France, the Netherlands and Germany and offices in Europe and Asia, focuses on specialty engineered products for the thermal/acoustical and filtration/separation markets.
Courtesy: Charter Medical Press Release